zotepine has been researched along with Acute Disease in 6 studies
zotepine: structure
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with acute exacerbation of schizophrenia (DSM-III-R criteria; n = 158) were allocated on a random, double-blind basis to receive zotepine (150 or 300 mg/day), chlorpromazine (300 or 600 mg/day) or placebo for 8 weeks." | 9.09 | A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. ( Butler, A; Cooper, SJ; Raniwalla, J; Tweed, J; Welch, C, 2000) |
| "Patients with acute exacerbation of schizophrenia (DSM-III-R criteria; n = 158) were allocated on a random, double-blind basis to receive zotepine (150 or 300 mg/day), chlorpromazine (300 or 600 mg/day) or placebo for 8 weeks." | 5.09 | A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. ( Butler, A; Cooper, SJ; Raniwalla, J; Tweed, J; Welch, C, 2000) |
| "This was a 6-week, multicenter, randomized, open-label, parallel-group, flexible dosing study." | 2.78 | An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. ( Chan, HY; Chen, KP; Chen, YY; Cheng, JS; Lin, AS; Tsai, CJ, 2013) |
| " The aim of this study was to test the first-generation atypical antipsychotic zotepine regarding its antimanic efficacy, tolerability and to find an adequate dosage for a loading strategy." | 1.33 | Zotepine loading in acute and severely manic patients: a pilot study. ( Amann, B; Dittmann, S; Dobmeier, M; Grunze, H; Mergl, R; Orth, M; Schaefer, M; Seemüller, F; Sterr, A, 2005) |
| " Within the dosage range of 50-450 mg (mean at the end of the study, 207 +/- 125 mg/day), a significant reduction of positive as well as negative symptoms was noted." | 1.31 | Zotepine in the treatment of acute hospitalized schizophrenic episodes. ( Barnas, C; Fabisch, H; Haushofer, M; Kasper, S; König, P; Lingg, A; Platz, T; Quiner, S; Rittmannsberger, H; Sackel, C; Stuppäck, C; Willeit, M; Zapotoczky, HG, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, HY | 1 |
| Lin, AS | 1 |
| Chen, KP | 1 |
| Cheng, JS | 1 |
| Chen, YY | 1 |
| Tsai, CJ | 1 |
| Amann, B | 1 |
| Sterr, A | 1 |
| Mergl, R | 1 |
| Dittmann, S | 1 |
| Seemüller, F | 1 |
| Dobmeier, M | 1 |
| Orth, M | 1 |
| Schaefer, M | 1 |
| Grunze, H | 1 |
| Cooper, SJ | 1 |
| Tweed, J | 1 |
| Raniwalla, J | 1 |
| Butler, A | 1 |
| Welch, C | 1 |
| Naber, D | 1 |
| Kasper, S | 1 |
| Quiner, S | 1 |
| Barnas, C | 1 |
| Fabisch, H | 1 |
| Haushofer, M | 1 |
| Sackel, C | 1 |
| König, P | 1 |
| Lingg, A | 1 |
| Platz, T | 1 |
| Rittmannsberger, H | 1 |
| Stuppäck, C | 1 |
| Willeit, M | 1 |
| Zapotoczky, HG | 1 |
| Klieser, E | 1 |
| Lehmann, E | 1 |
| Tegeler, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-centre Comparative Study to Evaluate the Anti-aggression Effect and Safety of Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward[NCT00418873] | Phase 4 | 39 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Study was stopped due to difficulty in patient enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for zotepine and Acute Disease
| Article | Year |
|---|---|
An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dibenzothiepins; Female; Hospitalization; Humans; Hyperp | 2013 |
A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Dibenzothiepins; Dose-Respon | 2000 |
[Double-blind comparison of 3 x 75 mg zotepine und 3 x 4 mg haloperidol in acute schizophrenic patients].
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Dibenzothiepins; Dose-Response Relationship, | 1991 |
3 other studies available for zotepine and Acute Disease
| Article | Year |
|---|---|
Zotepine loading in acute and severely manic patients: a pilot study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Diagnostic and Statistical Manual of M | 2005 |
[Atypical antipsychotics].
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; | 2000 |
Zotepine in the treatment of acute hospitalized schizophrenic episodes.
Topics: Acute Disease; Adult; Antipsychotic Agents; Austria; Dibenzothiepins; Drug Therapy, Combination; Fem | 2001 |